Exhibit 99.1
VCA Antech, Inc. Reports First Quarter 2008 Results and Reaffirms its Financial Guidance for 2008
- First quarter revenue increased 16.1% to $307.8 million
- First quarter gross profit increased 9.4% to $83.0 million
- First quarter diluted earnings per share increased 9.1% to $0.36
LOS ANGELES--(BUSINESS WIRE)--VCA Antech, Inc. (NASDAQ: WOOF), a leading animal healthcare company in the United States, today reported financial results for the first quarter ended March 31, 2008, as follows: revenue increased 16.1% to a first quarter record of $307.8 million; gross profit increased 9.4% to $83.0 million; operating income increased 10.5% to $60.0 million; net income increased 10.2% to $31.2 million; and diluted earnings per share increased 9.1% to $0.36.
Bob Antin, Chairman and CEO, stated, “I am pleased with our company’s performance in the first quarter of 2008. Faced with a challenging economic environment and the unusually high internal revenue growth experienced in the prior year, we delivered strong operating results through our continued focus on controlling costs. We continued our very successful acquisition program, acquiring 21 animal hospitals in the first quarter with annual revenues of over $45.0 million.
“Laboratory revenue in the first quarter increased 4.3% to $76.7 million driven primarily by internal revenue growth of 4.1%. Although our laboratory gross margin declined modestly to 48.7% in 2008 compared to 48.9% in the prior year, our operating margin remained constant at 42.2%.
“Animal hospital revenue in the first quarter increased 20.8% to $226.1 million driven by acquisitions, including Healthy Pet Corp. acquired on June 1, 2007, and same-store revenue growth of 1.9%. Our same-store animal hospital gross margin decreased slightly to 19.0% compared to 19.1% in the prior year. Consolidated animal hospital gross margin decreased to 18.2% in 2008 compared to 19.0% in 2007 due to lower margins at acquired hospitals. With the improved leverage on our selling, general and administrative costs, our operating margin decreased only slightly to 15.9% compared to 16.0% in the prior year.”
2008 Financial Guidance
We reaffirm our 2008 financial guidance as follows:
- Revenue from $1.30 billion to $1.33 billion
- Diluted earnings per common share from $1.55 to $1.60
Conference Call
We will discuss our company’s first quarter 2008 financial results during a conference call today, April 23, 2008, at 4:30 p.m. Eastern Time. You can access a live broadcast of the call by visiting our website at http://investor.vcaantech.com. You can also access the call via telephone by dialing (877) 591-4949. Interested parties should call at least 10 minutes prior to the start of the call to register.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may and likely will differ materially from the guidance provided in this release. Among the important factors that could cause actual results to differ are: a material adverse change in our financial condition or operations; the impact of adverse trends in the general economy on the rate of our laboratory internal revenue growth and animal hospital same-store revenue growth; the level of direct costs and our ability to maintain revenue at a level necessary to maintain expected operating margins; the level of selling, general and administrative costs; the effects of our recent acquisitions and our ability to effectively manage our growth and achieve operating synergies; a decline in demand for some of our products and services; any disruption in our information technology systems or transportation networks; the effects of competition; any impairment in the carrying value of our goodwill and other intangible assets; changes in prevailing interest rates; our ability to service our debt; and general economic conditions. These and other risk factors are discussed in our Report on Form 10-K for the year ended December 31, 2007, and the reader is directed to these statements for a further discussion of important factors that could cause actual results to differ materially from those in the forward-looking statements.
We own, operate and manage the largest networks of freestanding veterinary hospitals and veterinary-exclusive clinical laboratories in the country, and we supply diagnostic imaging equipment to the veterinary industry.
VCA Antech, Inc. |
Consolidated Income Statements |
(Unaudited - In thousands, except per share amounts) |
| | | | | | | | |
| | Three Months Ended |
| | March 31, |
| | 2008 | | | | | | 2007 |
Revenue: | | | | | | | | |
Laboratory | | $ | 76,729 | | | | | | | $ | 73,597 | |
Animal hospital | | | 226,100 | | | | | | | | 187,171 | |
Medical technology | | | 13,849 | | | | | | | | 11,172 | |
Intercompany | | | (8,846 | ) | | | | | | | (6,795 | ) |
| | | 307,832 | | | | | | | | 265,145 | |
| | | | | | | | |
Direct costs | | | 224,801 | | | | | | | | 189,225 | |
| | | | | | | | |
Gross profit: | | | | | | | | |
Laboratory | | | 37,342 | | | | | | | | 36,002 | |
Animal hospital | | | 41,137 | | | | | | | | 35,580 | |
Medical technology | | | 4,913 | | | | | | | | 4,311 | |
Intercompany | | | (361 | ) | | | | | | | 27 | |
| | | 83,031 | | | | | | | | 75,920 | |
| | | | | | | | |
Selling, general and administrative expense: | | | | | | | | |
Laboratory | | | 4,951 | | | | | | | | 4,967 | |
Animal hospital | | | 5,478 | | | | | | | | 5,560 | |
Medical technology | | | 3,434 | | | | | | | | 2,935 | |
Corporate | | | 9,315 | | | | | | | | 8,011 | |
| | | 23,178 | | | | | | | | 21,473 | |
| | | | | | | | |
Write-down and (gain) loss on sale of assets | | | (184 | ) | | | | | | | 122 | |
| | | | | | | | |
Operating income | | | 60,037 | | | | | | | | 54,325 | |
| | | | | | | | |
Interest expense, net | | | 7,615 | | | | | | | | 5,773 | |
Other expense | | | 177 | | | | | | | | 55 | |
Minority interest | | | 957 | | | | | | | | 846 | |
Income before provision for income taxes | | | 51,288 | | | | | | | | 47,651 | |
Provision for income taxes | | | 20,086 | | | | | | | | 19,338 | |
Net income | | $ | 31,202 | | | | | | | $ | 28,313 | |
| | | | | | | | |
Diluted earnings per share | | $ | 0.36 | | | | | | | $ | 0.33 | |
| | | | | | | | |
Shares used for computing diluted earnings per share | | | 85,865 | | | | | | | | 85,649 | |
VCA Antech, Inc. |
Consolidated Balance Sheets |
(Unaudited - In thousands) |
| | | | |
| | March 31, | | December 31, |
| | 2008 | | 2007 |
Assets | | | | |
Current assets: | | | | |
Cash and cash equivalents | | $ | 86,244 | | | $ | 110,866 | |
Trade accounts receivable, net | | | 48,445 | | | | 42,650 | |
Inventory | | | 25,100 | | | | 25,517 | |
Prepaid expenses and other | | | 15,246 | | | | 15,307 | |
Deferred income taxes | | | 14,659 | | | | 14,402 | |
Prepaid income taxes | | | - | | | | 8,160 | |
Total current assets | | | 189,694 | | | | 216,902 | |
Property and equipment, net | | | 220,879 | | | | 214,020 | |
Other assets: | | | | |
Goodwill | | | 866,096 | | | | 821,967 | |
Other intangible assets, net | | | 24,548 | | | | 22,373 | |
Deferred financing costs, net | | | 1,421 | | | | 1,537 | |
Other | | | 24,937 | | | | 9,912 | |
Total assets | | $ | 1,327,575 | | | $ | 1,286,711 | |
| | | | |
Liabilities and Stockholders' Equity | | | | |
Current liabilities: | | | | |
Current portion of long-term obligations | | $ | 7,794 | | | $ | 7,886 | |
Accounts payable | | | 29,998 | | | | 28,092 | |
Accrued payroll and related liabilities | | | 32,712 | | | | 38,341 | |
Income taxes payable | | | 8,673 | | | | - | |
Other accrued liabilities | | | 49,073 | | | | 42,074 | |
Total current liabilities | | | 128,250 | | | | 116,393 | |
Long-term obligations, less current portion | | | 550,411 | | | | 552,294 | |
Deferred income taxes | | | 27,871 | | | | 28,197 | |
Other liabilities | | | 10,709 | | | | 11,236 | |
Minority interest | | | 12,015 | | | | 10,207 | |
Stockholders' equity: | | | | |
Common stock | | | 84 | | | | 84 | |
Additional paid-in capital | | | 297,673 | | | | 296,037 | |
Retained earnings | | | 306,800 | | | | 275,598 | |
Accumulated other comprehensive loss | | | (6,238 | ) | | | (3,335 | ) |
Total stockholders' equity | | | 598,319 | | | | 568,384 | |
Total liabilities and stockholders' equity | | $ | 1,327,575 | | | $ | 1,286,711 | |
VCA Antech, Inc. |
Consolidated Statements of Cash Flows |
(Unaudited - In thousands) |
| | | | | |
| | | Three Months Ended |
| | | March 31, |
| | | 2008 | | 2007 |
Cash flows from operating activities: | | | | |
| Net income | | $ | 31,202 | | | $ | 28,313 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | | | | |
| Depreciation and amortization | | | 7,263 | | | | 5,931 | |
| Amortization of debt costs | | | 116 | | | | 61 | |
| Provision for uncollectible accounts | | | 820 | | | | 1,425 | |
| Write-down and (gain) loss on sale of assets | | | (184 | ) | | | 122 | |
| Share-based compensation | | | 1,309 | | | | 1,217 | |
| Minority interest in income of subsidiaries | | | 957 | | | | 846 | |
| Distributions to minority interest partners | | | (760 | ) | | | (645 | ) |
| Deferred income taxes | | | 2,329 | | | | 1,159 | |
| Excess tax benefit from exercise of stock options | | | (133 | ) | | | (922 | ) |
| Other | | | 86 | | | | (142 | ) |
| Changes in operating assets and liabilities: | | | | |
| Accounts receivable | | | (6,463 | ) | | | (6,040 | ) |
| Inventory, prepaid expenses and other assets | | | (2,351 | ) | | | (398 | ) |
| Accounts payable and other accrued liabilities | | | 2,767 | | | | (2,279 | ) |
| Accrued payroll and related liabilities | | | (5,629 | ) | | | (2,270 | ) |
| Income taxes | | | 16,946 | | | | 17,637 | |
| Net cash provided by operating activities | | | 48,275 | | | | 44,015 | |
Cash flows from investing activities: | | | | |
| Business acquisitions, net of cash acquired | | | (47,826 | ) | | | (32,203 | ) |
| Real estate acquired in connection with business acquisitions | | | (3,612 | ) | | | (7,929 | ) |
| Property and equipment additions | | | (9,463 | ) | | | (11,875 | ) |
| Proceeds from sale of assets | | | 1,747 | | | | 1,564 | |
| Other | | | (12,124 | ) | | | 110 | |
| Net cash used in investing activities | | | (71,278 | ) | | | (50,333 | ) |
Cash flows from financing activities: | | | | |
| Repayment of long-term obligations | | | (1,966 | ) | | | (2,302 | ) |
| Proceeds from issuance of common stock under stock option plans | | | 214 | | | | 839 | |
| Excess tax benefit from exercise of stock options | | | 133 | | | | 922 | |
| Net cash used in financing activities | | | (1,619 | ) | | | (541 | ) |
Decrease in cash and cash equivalents | | | (24,622 | ) | | | (6,859 | ) |
Cash and cash equivalents at beginning of period | | | 110,866 | | | | 45,104 | |
Cash and cash equivalents at end of period | | $ | 86,244 | | | $ | 38,245 | |
VCA Antech, Inc. | | | | |
Supplemental Operating Data | | | | |
(Unaudited - In thousands) | | | | |
| | As of |
Table #1 | | March 31, | | December 31, |
Selected consolidated balance sheet data | | 2008 | | 2007 |
| | | | |
Debt: | | | | |
Revolving credit facility | | $ | - | | | $ | - | |
Senior term notes | | | 526,327 | | | | 527,675 | |
Other debt and capital leases | | | 31,878 | | | | 32,505 | |
Total debt | | $ | 558,205 | | | $ | 560,180 | |
| | | | |
| | Three Months Ended |
Table #2 | | March 31, |
Selected expense data | | 2008 | | 2007 |
| | | | |
Rent expense | | $ | 10,208 | | | $ | 8,425 | |
| | | | |
| | | | |
Depreciation and amortization included in direct costs: | | | | |
Laboratory | | $ | 1,632 | | | $ | 1,338 | |
Animal hospital | | | 4,783 | | | | 3,815 | |
Medical technology | | | 307 | | | | 293 | |
Intercompany | | | (123 | ) | | | (89 | ) |
| | $ | 6,599 | | | $ | 5,357 | |
| | | | |
Depreciation and amortization included in selling, general and administrative expense | | | 664 | | | | 574 | |
Total depreciation and amortization | | $ | 7,263 | | | $ | 5,931 | |
| | | | |
| | | | |
Share-based compensation included in direct costs: | | | | |
Laboratory | | $ | 173 | | | $ | 183 | |
| | | | |
Share-based compensation included in selling, general and administrative expense: | | | | |
Laboratory | | | 202 | | | | 197 | |
Animal hospital | | | 333 | | | | 324 | |
Medical technology | | | 33 | | | | 28 | |
Corporate | | | 568 | | | | 485 | |
| | | 1,136 | | | | 1,034 | |
Total share-based compensation | | $ | 1,309 | | | $ | 1,217 | |
CONTACT:
VCA Antech, Inc.
Tomas Fuller, Chief Financial Officer, (310) 571-6505